1998 …2024
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

  • 14 Similar Profiles
Neoplasms Medicine & Life Sciences
Pediatrics Medicine & Life Sciences
Pharmacokinetics Medicine & Life Sciences
Rhabdomyosarcoma Medicine & Life Sciences
temozolomide Medicine & Life Sciences
Osteosarcoma Medicine & Life Sciences
Acute Myeloid Leukemia Medicine & Life Sciences
irinotecan Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2002 2024

resistance mechanisms

Research Output 1998 2019

5 Citations (Scopus)

A phase II study of alisertib in children with recurrent/refractory solid tumors or leukemia: Children's Oncology Group Phase I and pilot Consortium (ADVL0921)

Mosse, Y. P., Fox, E., Teachey, D. T., Reid, J. M., Safgren, S. L., Carol, H., Lock, R. B., Houghton, P. J., Smith, M. A., Hall, D., Barkauskas, D. A., Krailo, M., Voss, S. D., Berg, S. L., Blaney, S. M. & Weigel, B. J., Jun 1 2019, In : Clinical Cancer Research. 25, 11, p. 3229-3238 10 p.

Research output: Contribution to journalArticle

Open Access
Aurora Kinase A

Identification of aggressive Gardner syndrome phenotype associated with a de novo APC variant, c.4666dup

Kiessling, P., Dowling, E., Huang, Y., Ho, M. L., Balakrishnan, K., Weigel, B. J., Edward Highsmith, W., Niu, Z. & Schimmenti, L. A., Jan 1 2019, In : Cold Spring Harbor Molecular Case Studies. 5, 2, a003640.

Research output: Contribution to journalArticle

Open Access
Gardner Syndrome
Tooth Abnormalities
APC Genes

Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group

Kopp, L. M., Malempati, S., Krailo, M., Gao, Y., Buxton, A., Weigel, B. J., Hawthorne, T., Crowley, E., Moscow, J. A., Reid, J. M., Villalobos, V., Randall, R. L., Gorlick, R. & Janeway, K. A., Nov 1 2019, In : European Journal of Cancer. 121, p. 177-183 7 p.

Research output: Contribution to journalArticle

glembatumumab vedotin
3 Citations (Scopus)

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children’s Oncology Group

Malempati, S., Weigel, B. J., Chi, Y. Y., Tian, J., Anderson, J. R., Parham, D. M., Teot, L. A., Rodeberg, D. A., Yock, T. I., Shulkin, B. L., Spunt, S. L., Meyer, W. H. & Hawkins, D. S., Jan 15 2019, In : Cancer. 125, 2, p. 290-297 8 p.

Research output: Contribution to journalArticle

Open Access
Drug Therapy
3 Citations (Scopus)

A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group

Chuk, M. K., Widemann, B. C., Minard, C. G., Liu, X., Kim, A. R., Bernhardt, M. B., Kudgus, R. A., Reid, J. M., Voss, S. D., Blaney, S., Fox, E. & Weigel, B. J., Aug 1 2018, In : Pediatric Blood and Cancer. 65, 8, e27077.

Research output: Contribution to journalArticle

Open Access
Maximum Tolerated Dose